| Literature DB >> 28718805 |
Sophie Fraeyman1, Siska Croubels2, Mathias Devreese3, Gunther Antonissen4,5.
Abstract
Emerging Fusarium and Alternaria mycotoxins gain more and more interest due to their frequent contamination of food and feed, although in vivo toxicity and toxicokinetic data are limited. Whereas the Fusarium mycotoxins beauvericin, moniliformin and enniatins particularly contaminate grain and grain-based products, Alternaria mycotoxins are also detected in fruits, vegetables and wines. Although contamination levels are usually low (µg/kg range), higher contamination levels of enniatins and tenuazonic acid may occasionally occur. In vitro studies suggest genotoxic effects of enniatins A, A1 and B1, beauvericin, moniliformin, alternariol, alternariol monomethyl ether, altertoxins and stemphyltoxin-III. Furthermore, in vitro studies suggest immunomodulating effects of most emerging toxins and a reproductive health hazard of alternariol, beauvericin and enniatin B. More in vivo toxicity data on the individual and combined effects of these contaminants on reproductive and immune system in both humans and animals is needed to update the risk evaluation by the European Food Safety Authority. Taking into account new occurrence data for tenuazonic acid, the complete oral bioavailability, the low total body clearance in pigs and broiler chickens and the limited toxicity data, a health risk cannot be completely excluded. Besides, some less known Alternaria toxins, especially the genotoxic altertoxins and stemphyltoxin III, should be incorporated in risk evaluation as well.Entities:
Keywords: Alternaria; Fusarium; emerging mycotoxin; occurrence; toxicity; toxicokinetics
Mesh:
Substances:
Year: 2017 PMID: 28718805 PMCID: PMC5535175 DOI: 10.3390/toxins9070228
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Chemical structure of beauvericin, enniatin A, A1, B and B1. Beauvericin (BEA), R1 = R2 = R3 = phenylmethyl; Enniatin A (ENN A), R1 = R2 = R3 = –CH(CH3)CH2CH3; Enniatin A1 (ENN A1), R1 = R2 = –CH(CH3)CH2CH3, R3 = –CH(CH3)2; Enniatin B (ENN B), R1 = R2 = R3 = –CH(CH3)2; Enniatin B1 (ENN B1), R1 = R2 = –CH(CH3)2, R3 = –CH(CH3)CH2CH3.
Occurrence of emerging Fusarium and Alternaria mycotoxins in food and feed.
| Commodity | Mycotoxin | Total # Samples Analyzed | Prevalence Range (%) | Concentration Range (µg/kg) | Origin of Sample with Maximum Concentration | Reference |
|---|---|---|---|---|---|---|
| Cereals (unprocessed) a | BEA | 482 | 12–100 | <10–327 | Sweden | [ |
| ENNs b | 482 | 96–100 | Finland | [ | ||
| MON | 590 | 0.88–100 | <15–2606 | Italy | [ | |
| AOH | 1582 | 2.4–47 | 0.75–832 | Germany | [ | |
| AME | 1582 | 3.1–7.1 | 0.3–905 | Germany | [ | |
| TeA | 1526 | 15–68 | 0.1–4224 | Germany | [ | |
| ALT | 1106 | 2.63–7.1 | 6–196.6 | Germany | [ | |
| ATX-I | 42 | 2.4 | 43 | South Africa | [ | |
| TEN | 370 | 77 | 0.4–258.6 | China | [ | |
| Rice | BEA | 70 | 75.7 | 3800–26,300 | Morocco | [ |
| ENN A | 70 | 22.8 | 8400–119,500 | Morocco | [ | |
| ENN A1 | 70 | 5.7 | 56,200–448,700 | Morocco | [ | |
| ENN B | 70 | 30 | 4400–26,200 | Morocco | [ | |
| ENN B1 | 70 | 24.3 | 3600–23,700 | Morocco | [ | |
| Cereal products | BEA | 354 | 0–17.5 | 0.1–10,600 | Morocco | [ |
| ENN A | 354 | 2.9–77 | 0.5–29,700 | Morocco | [ | |
| ENN A1 | 354 | 30–100 | 0.25–688,000 | Morocco | [ | |
| ENN B | 354 | 13.2–100 | 0.5–81,100 | Morocco | [ | |
| ENN B1 | 354 | 17.6–100 | 0.5–795,000 | Morocco | [ | |
| AOH | 83 | 31–89 | 8–121 | Italy | [ | |
| AME | 83 | 26–89 | <0.4–48 | Italy | [ | |
| TeA | 9 | 100 | <100–210 | Germany | [ | |
| TEN | 9 | 100 | <1.6–12 | Germany | [ | |
| Tomato products c | AOH | 187 | 28–70.6 | <2–41.6 | Belgium | [ |
| AME | 187 | 20–79 | <0.9–7.8 | The Netherlands | [ | |
| TeA | 187 | 40–100 | <5–462 | The Netherlands | [ | |
| ALT | 83 | 32–56 | 6.1–62.0 | Belgium | [ | |
| TEN | 117 | 21–64 | <3.9–8.9 | Belgium | [ | |
| AOH-3-sulfate | 83 | 11–26 | 2.6–8.7 | Belgium | [ | |
| AME-3-sulfate | 83 | 32–78 | 1.7–9.9 | Belgium | [ | |
| Fruit juices d | AOH | 101 | 15–100 | <0.2–16 | Germany | [ |
| AME | 101 | 25–100 | <0.13–4.9 | Germany | [ | |
| TeA | 101 | 8–100 | <1.1–250 | Germany | [ | |
| ALT | 101 | 4.3–100 | 1.18–18.4 | Germany | [ | |
| TEN | 101 | 22–100 | <0.5–10.27 | Germany | [ | |
| altenuic acid | 78 | 100 | 2.71 | Germany | [ | |
| altenuisol | 78 | 8–50 | <0.74–5.58 | Germany | [ | |
| Infant food e | TeA | 40 | 100 | 0.8–1200 | Germany | [ |
| Wines | AOH | 30 | 20–93 | 0.65–11 | The Netherland | [ |
| AME | 25 | 93 | 0.8–1.45 | Germany | [ | |
| TeA | 25 | 60–100 | <1–60 | Germany | [ | |
| TEN | 25 | 71 | 1.01–1.47 | Germany | [ | |
| altenuic acid | 25 | 21–64 | <1–6.1 | Germany | [ | |
| altenuisol | 25 | 55–71 | <0.74–2.91 | Germany | [ | |
| Dried figs and olives | AOH | 14 | 7 | 8.7 | The Netherlands | [ |
| TeA | 19 | 10–100 | 5.3–2345 | The Netherlands | [ | |
| Vegetable oil | AOH | 19 | 47 | ≤6 | Germany | [ |
| AME | 19 | 84 | <1.1–14 | Germany | [ | |
| TeA | 19 | 21 | 15 | Germany | [ | |
| TEN | 19 | 47 | <6.6–11 | Germany | [ | |
| Sunflower seeds and oils | AOH | 35 | 10–55 | <4.9–39 | Germany | [ |
| AME | 35 | 9–64 | <0.5–17 | The Netherlands | [ | |
| TeA | 40 | 80–100 | <5–1350 | The Netherlands | [ | |
| ALT | 11 | 9 | <14 | Germany | [ | |
| ATX-I | 11 | 9 | <45 | Germany | [ | |
| TEN | 16 | 20–91 | <3.7–800 | Germany | [ | |
| Feed | BEA | 1345 | 50–98 | <2–2326 | not specified | [ |
| ENN A | 1315 | 0–87 | <0.1–1745 | not specified | [ | |
| ENN A1 | 1315 | 12–95 | <0.15–2216 | not specified | [ | |
| ENN B | 1414 | 28–92 | <0.3–1514 | not specified | [ | |
| ENN B1 | 1315 | 12–92 | <0.2–1846 | not specified | [ | |
| MON | 1315 | 3–79 | <2–12,236 | not specified | [ | |
| AOH | 264 | 0–80 | 17–221 | not specified | [ | |
| AME | 264 | 1.5–82 | <6–733 | not specified | [ | |
| TeA | 83 | 65 | not specified-1983 | not specified | [ |
a Including wheat, oats, barley and rye; b Sum of different ENNs or not specified; c Including tomato sauce, paste, pieces, concentrate, pieces and ketchup; d Including apple, apricot, carrot, citrus, currant, grape, grapefruit, multi fruit, orange, sour cherry and vitaminized (ACE) juice; e Including tea infusions, puree infant food and cereals.
In vitro toxicity of emerging Fusarium and Alternaria mycotoxins.
| Cell Line | Mycotoxin | Exposure Time | Exposure Dose (µM) | Effect | Reference |
|---|---|---|---|---|---|
| Caco-2 a | BEA | 0 min | 1.5 | ROS b generation | [ |
| 24–72 h | IC50: 20.6–3.2 µM (MTT c); IC50: 8.8–1.9 µM (NR d) | ||||
| 24–72 h | 1.5–3.0 | LPO e, ↓ GSH, ↑ GSSG, loss of mitochondrial membrane potential, cell cycle arrest in S and G2/M, apoptosis and necrosis | |||
| 24 h | 12 | DNA damage | |||
| ENN A | <1 h | 1.5–3.0 | ROS generation | ||
| 24–72 h | IC50: 9.3–0.46 µM | ||||
| 24–72 h | 1.5–3.0 | LPO, loss of mitochondrial membrane potential, cell cycle arrest in SubG0/G1 and (Sub)G2/M, DNA damage, apoptosis and necrosis | |||
| ENN A1 | 10 min | 1.5 | ROS generation | ||
| 24–72 h | IC50: 12.3–0.46 µM | ||||
| 24–72 h | 1.5–3.0 | LPO, loss of mitochondrial membrane potential, DNA damage, cell cycle arrest in (Sub)G0/G1 and G2/M, apoptosis, necrosis | |||
| ENN B | 10 min | 3.0 | ROS generation | ||
| 48–72 h | IC50: 10.7–1.4 µM | ||||
| 24–72 h | 1.5–3.0 | LPO, loss of mitochondrial membrane potential, cell cycle arrest in (Sub)G0/G1, and G2/M, apoptosis, necrosis | |||
| ENN B1 | 5–10 min | 1.5–3.0 | ROS generation | ||
| 48–72 h | IC50: 10.8–0.8 µM | ||||
| 24–74 h | 1.5–3.0 | LPO, loss of mitochondrial membrane potential, DNA damage, cell cycle arrest in (Sub) G0/G1, G2/M and S, apoptosis, necrosis | |||
| MON | 72 h | IC50: 30.9 µg/mL | |||
| AOH | 24 h | 15–30 | changes in MMP f, ↓ G1 phase, ↑ S and G2/M phase, apoptosis, necrosis | ||
| HT-29 g | ENN A | 24–48 h | IC50: 9.3–8.2 µM | [ | |
| ENN A1 | 24–48 h | IC50: 9.1–1.4 µM | |||
| ENN B | 24–48 h | IC50: ≥2.8 µM | |||
| ENN B1 | 24–48 h | IC50: 16.8–3.7 µM | |||
| HCT116 g | AOH | IC50, 24h: 65 µM | [ | ||
| AME | IC50, 24h: 120 µM | ||||
| IPEC-J2 i | BEA | 24–72 h | 5–10 | TEERj reduction (between −59% and −80%), no reduction of cell viability | [ |
| ENN A | 72 h | 5 | TEER reduction (−70%), no reduction of cell viability | ||
| ENN A1 | 24–72 h | 10 | TEER reduction (between −29% and −74%), no reduction of cell viability | ||
| ENN B | 48–72 h | 2.5 | TEER reduction (between −55% and −68%), no reduction of cell viability | ||
| ENN B1 | 48–72 h | 5 | TEER reduction (between −44% and −58%), no reduction of cell viability | ||
| ENN combinations | 1.5 | additive effect on TEER reduction | |||
| MON | 72 h | 5–10 | no effect on TEER or viability | [ | |
| Hep-G2 k | ENN A | 24–48 h | IC50: 26.2–11.4 µM | [ | |
| ENN A1 | 24–48 h | IC50: 11.6–2.6 µM | |||
| ENN B | 24–48 h | IC50: >30 µM | |||
| ENN B1 | 24–48 h | IC50: 24.3–8.5 µM | |||
| MON | 48–72 h | IC50: 39.5–24.1 µg/mL | |||
| H295R l | ENN B | 72 h | 10–100 | ↓ viability by 37%, ↑ S-phase, ↓ G0/G1phase, ↑ apoptosis | [ |
| AOH | 3.87 | no influence on viability | |||
| H29R l | AOH | no effect on testosterone and cortisol levels | [ | ||
| neonatal Leydig cells | ENN B | 10–100 | ↓ viability by 20%, ↓ estradiol in unstimulated cells | [ | |
| human breast adenocarcinoma RGA cell line | AOH | agonistic estrogen response, relative estrogenic potential: 0.0004% and equivalent estrogenic quantity of 17β-estradiol: 2.9 fg/mL | [ | ||
| cell free buffer | AOH | binding affinity to ERα: 10,000× lower compared to 17β-estradiol | [ | ||
| Ishikawa human endometrial adenocarcinoma cell line | AOH | 2.5–10 | ↑ alkaline phosphatase mRNA and activity | [ | |
| porcine oocytes and embryos | BEA | >0.5 | ↓ rate of development of maturing oocyte and 2–4 cell stage embryo, activated oocytes and 2–4 cell stage embryos more sensitive than maturing oocytes, compromised cytoplasmic maturation and abnormal meiosis in oocytes, ↓ cumulus viability and progesterone synthesis, cumulus cells control intracellular BEA through MDR1 activity, in oocytes mitochondrial function was altered, altered gene expression in cumulus cells and oocytes, altered MDR1 activity in activated oocytes, ↓ viability embryo | [ | |
| pig granulosa cells | AOH | 0.8–1.6 | ↓ cell viability, ↓ progesterone levels, ↓ P450scc | [ | |
| AME | 0.8–1.6 | ↓ cell viability, ↓ progesterone levels, ↓ P450scc | |||
| TeA | 6.4–100 | no influence on viability | |||
| bovine granulosa cells | BEA | 3 | ↓ estradiol and progesterone production | [ | |
| 6–10 | ↓ (fetal calf serum-induced) proliferation | ||||
| CHO-K1 m | BEA | 24–72 h | IC50: 10.7–2.2 µM | [ | |
| ENN A | 24–72 h | >7.5–2.83 µM | |||
| ENN A1 | 24–72 h | 8.8–1.65 µM | |||
| ENN B | 24–72 h | 11.0–2.44 µM | |||
| ENN B1 | 24–72 h | 4.53–2.47 µM | |||
| ENN combinations | 24 h | additive effects: A + B1, A1 + B, B + B1 | |||
| MON | IC50: >100 µg/mL | ||||
| THP-1 p monocyte | AOH | 24–48 h | 7.5–15 | cell cycle arrest in S- and G2/M-phase | [ |
| ↓ CD14 and CD11b upregulation during macrophage differentiation | |||||
| ↓ downregulation of CD71 during macrophage differentiation, | |||||
| +DON: additive effect | |||||
| CCRF-CEM q | BEA | 24 h | 1 | cytotoxicity, apoptosis | [ |
| human lymphocytes | MON | 48 h | 10–25 | chromosome breaks, chromatid breaks and exchanges, polyploidy, | [ |
| human immature dendritic cells | BEA | IC50: 1.0 µM | [ | ||
| ENN B | IC50: 1.6 µM | ||||
| MON | 80 | 20% mortality, ↓ endocytosis, ↓ CD1a expression | |||
| human mature dendritic cells | BEA | IC50: 2.9 µM, ↓ CCR7 expression, ↑ IL-10 concentration | [ | ||
| ENN B | IC50: 2.6 µM, ↓ CD80, CD86 and CCR7 expression, ↑ IL-10 | ||||
| MON | 80 | 20% mortality | |||
| human macrophages | BEA | ≥0.5 | IC50: 2.5 µM, ↓ endocytosis | [ | |
| ENN B | IC50: 2.5 µM, ↓ endocytosis, ↑ CD71 | ||||
| MON | ↓ endocytosis, ↓ CD71, ↓ HLA-DR | ||||
| AOH | 24 h | 30 | changed morphology: from round to elongated with dendrite-like protrusions | ||
| RAW 2654.7 mouse macrophage | AOH | 24–48 h | 30 | changed morphology: from round to flattened, star-shaped or elongated spindle-shaped cells | [ |
| mouse hemidiaphragm preparation | BEA | 5 | inhibition (in) directly elicited tetanic muscle contraction; inhibition nerve-evoked and directly elicited muscle twitches, reduction amplitude and frequency of miniature endplate potentials | [ | |
| 1 h | 7.5 | inhibition directly elicited twitches, induction contracture, decrease resting membrane potential | |||
| 1 h | 10 | complete block of (in) directly elicited isometric muscle contraction, amplitude reduction of directly elicited muscle twitch, decrease resting membrane potential | |||
| C5-O r | MON | 72 h | IC50: 34.2 µg/mL | [ | |
| V79 s | MON | 72 h | IC50: >100 µg/mL | [ | |
| AOH | 5–50 | induction of micronuclei cell cycle arrest in G2 and S phase |
↓ decrease; ↑ increase; a human adenocarcinoma colon cells; b reactive oxygen species; c tetrazolium salt reduction assay; d Neutral Red assay; e lipid peroxidation; f mitochondrial membrane permeabilization; g human colon carcinoma cells; h permeability transition pore; i intestinal porcine epithelial cells from the jejunum; j transepithelial electrical resistance; k human hepatocellular carcinoma cells; l human adrenocortical carcinoma cells; m Chinese hamster ovary cells; n patulin; o sterigmatocystin; p human acute monocyte leukemia cell line; q human leukemia cells; r Balb/c mice keratinocyte cells; s Chinese hamster lung fibroblast.
Figure 2The chemical structure of moniliformin. X=H, Na or K.
In vivo toxicity of moniliformin and Alternaria mycotoxins.
| Animal Species | Mycotoxin | Route of Exposure | Exposure Time | Exposure Dose | Effect | Reference |
|---|---|---|---|---|---|---|
| mouse | MON | po-ip | 1x | LD50: 20.9 (♀) 29.1 (♂) mg/kg bw (ip), survivors clinically healthy | [ | |
| TeA | iv-po | 1x | 0–398 mg/kg bw | LD50: 76–162 (iv) and 81–209 (po), vomiting, diarrhea, hemorrhages, death | ||
| Sprague-Dawley rats | MON | po | 1x | 5 mg/kg bw | no clinical signs | [ |
| 1x | 10 mg/kg bw | ↓ activity for 24 h, respiratory changes, trembling, piloerection, complete recovery within 48 h | ||||
| 1x | 25–50 mg/kg bw | respiratory and cardiovascular changes, collapse, convulsion and death within 48–83 min | ||||
| 28 days | 3–6 mg/kg bw | no clinical symptoms, no effect on leucocyte and red blood cell counts, food and water consumption or organ and body weights, ↓ phagocytic activity of neutrophils | ||||
| TeA | iv-po | 1x | 0–398 mg/kg bw | LD50: 83–157 (iv) and LD50: 168–240 (po), vomiting, diarrhea, hemorrhages, death | ||
| Syrian golden hamster | AME | ip | 1x | 200 mg/kg bw | severe necrosis and coalescence of visceral organs | [ |
| chicken embryo | MON | injection | 1x | LD50: 2.8 µg/egg, no gross teratogenic effects in survivors | [ | |
| TeA | injection | 1x | 150–1500 µg/egg | dose-related mortality, LD50: 548 µg/egg | [ | |
| 1-day old chicken | MON | po | 1x | 0–16 mg/kg bw | LD50: 5.4 mg/kg bw (crop intubation), survivors clinically healthy | [ |
| broiler chickens | MON | feed | 21 days | 200 mg/kg feed | death (56%) | [ |
| 100 mg/kg feed | ↓ feed intake and body weight gain | |||||
| feed | 42 days (day 7–49) | 50 mg/kg feed | mortality (13.3%) | |||
| 25 mg/kg feed | mortality (7.8%) | |||||
| TeA | po | 21 days | 1.25–2.5 mg/kg bw | ↓ weight gain and feed efficiency | ||
| White leghorn chicken | TeA | po | 1x | LD50: 37.5 mg/kg bw with hemorrhages of the musculature of the thigh, breast, heart and subcutaneous tissues | [ | |
| 21 days | 0.63 mg/kg bw | pathological changes in spleen and gizzard but no extensive hemorrhages | ||||
| 21 days | 1.25–2.5 mg/kg bw | ↓ weight gain and feed efficiency | ||||
| turkeys | MON | feed | 91 days (day 7–98) | 25, 37.5, 50 mg/kg feed | ↑ relative heart weight | [ |
| 37.5, 50 mg/kg feed | ↑ relative liver weight | |||||
| 50 mg/kg feed | loss of cardiomyocyte cross striations | |||||
| turkey poults | MON | feed | 21–28 days | 100 mg/kg feed | ↓ feed intake, body weight gain, feed efficiency, ↓ relative thymus, bursa and spleen weights, | [ |
| Japanese quail | MON | feed | 35 days | 100 mg/kg feed | cardiomegaly, myocardial congestion, hypertrophy, myocardial disarray, ↑ mitochondria, resulting in separation of muscle fibers, swollen and deformed mitochondria with degenerative changes. Congestion, hemorrhages and degenerative changes more pronounced and extensive disruption of muscle fibers and destruction of Z-bands when feed contained both MON and fumonisin B1. Death. | [ |
| barrow | MON | feed | 28 days | 100 mg/kg feed | acute mortality due to apparent cardiac failure | [ |
| dog | TeA | iv-po | 1x | 25–50 mg/kg bw | severe tachycardia, massive diffuse hemorrhages, (bloody) diarrhea | [ |
| iv | 3x | 20 mg/kg bw | severe hemorrhagic gastro-enteropathy, death | |||
| iv-po | 6–30 days | 0.0625–11.2 mg/kg bw | salivation, emesis, tachycardia, hemorrhagic gastro-enteropathy, death | |||
| monkey | TeA | iv | 3x | 20 mg/kg bw | severe hemorrhagic gastro-enteropathy, death | [ |
| iv-po | 7–45 days | 11.2–89.6 mg/kg | salivation, emesis, hemorrhagic gastro-enteropathy, death |
↓ decrease; ↑ increase.
Figure 3Structure of the Alternaria mycotoxins alternariol (AOH), alternariol monomethyl ether (AME), altenuene (ALT), tenuazonic acid (TeA), altertoxins- (ATX-) I, II and III and stemphyltoxin III (STTX-III).